Late-Breaking Data at AACR 2022: Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming CAMBRIDGE, Mass, April 10, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today presented new late-breaking data at the American Association for […]